Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 26, 2015 2:36 AM ET


Company Overview of King Pharmaceuticals LLC

Company Overview

King Pharmaceuticals LLC develops, manufactures, and markets prescription pharmaceutical products and animal health products worldwide. It offers branded prescription pharmaceuticals including neuroscience products such as Skelaxin, Flector Patch, Avinza, and Embeda; hospital products such as Thrombin-JMI; and legacy products including Levoxyl, Bicillin, Altace, and Cytomel to general/family practitioners, internal medicine physicians, neurologists, pain specialists, surgeons, and hospitals. The company’s animal health business focuses on medicated feed additives and water-soluble therapeutics which are anti-infective products primarily for poultry, cattle, and swine markets. It also manufac...

501 Fifth Street

Bristol, TN 37620

United States

Founded in 1993

2,640 Employees





Key Executives for King Pharmaceuticals LLC

Executive Vice President of Managed Markets, Government Trade and Public Policy
Chief Legal Officer and Corporate Secretary
Age: 53
Executive Vice President of Technical Operations and Manufacturing
Chief Science Officer
Age: 62
Corporate Compliance Officer
Age: 63
Compensation as of Fiscal Year 2014.

King Pharmaceuticals LLC Key Developments

King Pharmaceuticals LLC to Pay $2.2 Million Civil Penalty

King Pharmaceuticals LLC will pay $2.2 million and take measures to comply with the Clean Air Act to resolve alleged violations of the Clean Air Act (CAA) at its pharmaceutical manufacturing facility located in Bristol, Tenn., announced the Department of Justice, the U.S. Environmental Protection Agency (EPA), and the Tennessee Department of Environment and Conservation (TDEC). From the $2.2 million civil penalty, $1.1 million will be paid to the United States and $1.1 million will be paid to TDEC. From TDECs $1.1 million penalty, $650,000 will be applied to a TDEC state project for homeowners. The settlement also requires the facility to demonstrate compliance with CAA National Emission Standards for Pharmaceuticals Production (PharmaMACT regulations) and to apply for a Title V permit.

Similar Private Companies By Industry

Company Name Region
Asphelia Pharmaceuticals, Inc. United States
TREVENTIS Corporation United States
Dartmouth-Hitchcock Clinic United States
Next Breath LLC United States
Anti-Depression BioHealth Solutions, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact King Pharmaceuticals LLC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at